Market Overview:
The global Clostridium difficile infection treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of Clostridium difficile infections, rising demand for novel therapies, and growing number of approvals for new drugs. The global Clostridium difficile infection treatment market is segmented on the basis of type into oral and injectable therapies. The oral therapy segment is expected to dominate the global Clostridium difficile infection treatment market during the forecast period owing to its high adoption rate and easy availability. However, the injectable therapy segment is projected to grow at a higher CAGR during the forecast period due to its better efficacy than oral therapies in treating severe cases of clostridial diarrhea. On the basis of application, hospitals pharmacies accounted for majority share in 2017 and are expected to maintain their dominance throughoutthe forecast period. This can be attributedto th efact that hospital pharmacies are one stop shopsfor all prescription medications required by patients admitted in hospitals .This would provide opportunities for players operatingin thismarket segmentsince these channels caterto a wider customer base as compared toretail pharmacists or drugstores .
Product Definition:
Clostridium difficile infection (CDI) is a type of bacterial infection that can cause severe diarrhea. CDI is caused by the bacterium Clostridium difficile, which produces toxins that can damage the lining of the intestine. CDI most often affects people who have been recently hospitalized and received antibiotics or those who have a weakened immune system.
Treatment for CDI depends on the severity of symptoms. Mild cases may be treated with antibiotics such as metronidazole or vancomycin, while more severe cases may require hospitalization and treatment with intravenous antibiotics. Treatment with probiotics (such as Saccharomyces boulardii) may also be helpful in some cases.
Oral:
Oral is an antibiotic drug that attacks the bacteria in the gut that causes C. difficile infection (CDI). Oral can be used in two ways, as a standalone therapy or combined with vancomycin for enhanced effect. The drug was approved by the U.S Food and Drug Administration (FDA) in June 2006 as a treatment for CDI and it gained market approval across Europe soon after.
Injectable:
Injectable is a drug that is administered by injection into the muscle, vein, or under the skin. The drug works by blocking certain pain signals to allow relief from cramps and spasms. In addition, it also prevents diarrhea and vomiting caused due to infection. It allows proper functioning of the digestive system for better absorption of nutrients in food as well as helps in maintaining hydration level during treatment process.
Application Insights:
The hospital pharmacies segment dominated the global market in 2017. This can be attributed to factors such as presence of a large patient base with C. difficile infection and high prevalence of healthcare facilities in developed countries like the U.S., Canada, U.K., Germany and France where most hospitals have their own pharmacies department which caters Clostridium difficile infection treatment needs of patients¢â‚¬â„¢ medication at low cost as compared to retail pharmacies or drug stores without compromising quality care delivery system for patients infected with C Difficile Infection (CDI).
In addition, growing awareness among people about CDI is increasing demand for antibiotic treatments that are effective against this bacterial infection is also driving hospital pharmacists to provide better treatment options leading to increased market share over the forecast period especially in Europe.
Regional Analysis:
North America dominated the global market in 2017. The presence of sophisticated healthcare infrastructure, high patient awareness levels coupled with relatively higher healthcare spending in this region are some factors responsible for its large share. Moreover, increasing number of treatment options and favorable reimbursement policies are also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to rising geriatric population and lifestyle stressors that increase susceptibility to infections such as Clostridium difficile infection (CDI). In addition, improving economic conditions in emerging countries such as India and China are further expected to boost product demand during the forecast period. Furthermore, an increase in government initiatives for CDI diagnosis & treatment is also likely contribute towards regional growth over the next eight years time span. For instance; In April 2016; Ministry Of Health And Family Welfare.
Growth Factors:
- Rising incidence of Clostridium difficile infection (CDI) due to increasing number of hospital admissions and prevalence of risk factors such as use of antibiotics and advanced age
- Growing demand for effective CDI treatments owing to the high mortality rates associated with the disease
- Increasing research and development activities for novel CDI therapies
- Technological advancements in diagnosis and treatment of CDI
- rising healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Clostridium Difficile Infection Treatment Market Research Report
By Type
Oral, Injectable
By Application
Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Sales
By Companies
Merck, Baxter International, Sanofi, Pfizer, Novartis, Astellas Pharma, Eli Lilly, AstraZeneca, Actelion Pharmaceuticals, Mylan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
177
Number of Tables & Figures
124
Customization Available
Yes, the report can be customized as per your need.
Global Clostridium Difficile Infection Treatment Market Report Segments:
The global Clostridium Difficile Infection Treatment market is segmented on the basis of:
Types
Oral, Injectable
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Sales
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Baxter International
- Sanofi
- Pfizer
- Novartis
- Astellas Pharma
- Eli Lilly
- AstraZeneca
- Actelion Pharmaceuticals
- Mylan
Highlights of The Clostridium Difficile Infection Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injectable
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Sales
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Clostridium Difficile Infection Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Clostridium difficile infection (C. diff) is a serious, potentially life-threatening illness caused by the bacterium Clostridium difficile. C. diff can cause severe diarrhea and abdominal pain in people of all ages, but it is particularly dangerous for people with weakened immune systems or who are taking antibiotics regularly. Treatment typically involves antibiotics to kill the bacteria and supportive care, such as hydration and nutrition therapy. If left untreated, C. diff can lead to serious health complications including death
Some of the key players operating in the clostridium difficile infection treatment market are Merck, Baxter International, Sanofi, Pfizer, Novartis, Astellas Pharma, Eli Lilly, AstraZeneca, Actelion Pharmaceuticals, Mylan.
The clostridium difficile infection treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Clostridium Difficile Infection Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Clostridium Difficile Infection Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Clostridium Difficile Infection Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Clostridium Difficile Infection Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Clostridium Difficile Infection Treatment Market Size & Forecast, 2018-2028
4.5.1 Clostridium Difficile Infection Treatment Market Size and Y-o-Y Growth
4.5.2 Clostridium Difficile Infection Treatment Market Absolute $ Opportunity
Chapter 5 Global Clostridium Difficile Infection Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Clostridium Difficile Infection Treatment Market Size Forecast by Type
5.2.1 Oral
5.2.2 Injectable
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Clostridium Difficile Infection Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Clostridium Difficile Infection Treatment Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Drug Stores
6.2.4 Online Sales
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Clostridium Difficile Infection Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Clostridium Difficile Infection Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Clostridium Difficile Infection Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Clostridium Difficile Infection Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Clostridium Difficile Infection Treatment Market Size Forecast by Type
9.6.1 Oral
9.6.2 Injectable
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Clostridium Difficile Infection Treatment Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Drug Stores
9.10.4 Online Sales
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Clostridium Difficile Infection Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Clostridium Difficile Infection Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Clostridium Difficile Infection Treatment Market Size Forecast by Type
10.6.1 Oral
10.6.2 Injectable
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Clostridium Difficile Infection Treatment Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Drug Stores
10.10.4 Online Sales
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Clostridium Difficile Infection Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Clostridium Difficile Infection Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Clostridium Difficile Infection Treatment Market Size Forecast by Type
11.6.1 Oral
11.6.2 Injectable
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Clostridium Difficile Infection Treatment Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Drug Stores
11.10.4 Online Sales
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Clostridium Difficile Infection Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Clostridium Difficile Infection Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Clostridium Difficile Infection Treatment Market Size Forecast by Type
12.6.1 Oral
12.6.2 Injectable
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Clostridium Difficile Infection Treatment Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Drug Stores
12.10.4 Online Sales
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Clostridium Difficile Infection Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Clostridium Difficile Infection Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Clostridium Difficile Infection Treatment Market Size Forecast by Type
13.6.1 Oral
13.6.2 Injectable
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Clostridium Difficile Infection Treatment Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Drug Stores
13.10.4 Online Sales
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Clostridium Difficile Infection Treatment Market: Competitive Dashboard
14.2 Global Clostridium Difficile Infection Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Baxter International
14.3.3 Sanofi
14.3.4 Pfizer
14.3.5 Novartis
14.3.6 Astellas Pharma
14.3.7 Eli Lilly
14.3.8 AstraZeneca
14.3.9 Actelion Pharmaceuticals
14.3.10 Mylan
